Anumana expands AI cardiac care platform with support from Boston Scientific
Related Articles
FDA grants breakthrough designation for Anumana’s ECG-AI algorithm
Medical Device Network: The US Food and Drug Administration (FDA) has granted breakthrough device designation (BDD) for the electrocardiogram-artificial intelligence (ECG-AI) algorithm by AI-driven health technology company Anumana. The algorithm…{post_date: F d, Y}
Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the…{post_date: F d, Y}
Inside Mayo Clinic’s AI Factory: How Mayo Clinic is looking to use AI to enhance patient care and clinical decision making
AI Data & Analytics Network: One of the most consequential applications of artificial intelligence (AI) and machine learning (ML) is medicine. Though medical AI is still in its infancy, experts predict that within the…{post_date: F d, Y}
Anumana Makes Educated Inferences in Heart Failure
Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical…{post_date: F d, Y}